Similar effects on mePP2ACα and PP2ACα were detected across a panel of KRAS-mutant NSCLC cell lines treated with trametinib and adagrasib (Figure 1, C and D, and Supplemental Figures 6 and 7). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.